Inadvertent Dexamethasone Implant Injection into the Lens Body Management

Berarducci, Antonio; Sian, Inderpaul S.; Ling, R

doi:10.5301/ejo.5000436

Cited by 33 publications

(31 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 patients had malpositioned implants, which occurred within the first two months of our institution. Similar cases have been reported elsewhere in the literature [20,21]. Following a review of our local procedure, there was a change in injection technique and we have not experienced any further episodes.…”

Section: Complicationssupporting

confidence: 83%

Untitled

2015

OCR

View full text Add to dashboard Cite

Section: Complicationssupporting

confidence: 83%

Untitled

2015

OCR

View full text Add to dashboard Cite

“…There have been reports of intralenticular Ozurdex leading to cataract progression in days or months after injection and rise in intraocular pressure requiring intervention. [367] Progression of cataract might take as long as 11 months after injection and might require a second Ozurdex injection for macular edema in the presence of intralenticular Ozurdex. [2] In our case, there was no progression of cataract and intraocular pressure was normal during the entire follow-up.…”

Section: Discussionmentioning

confidence: 99%

Immortal Ozurdex: A 10-month follow-up of an intralenticular implant

Poornachandra

Kumar

Jayadev

et al. 2017

Indian J Ophthalmol

View full text Add to dashboard Cite

A 78-year-old male who had received a dexamethasone implant (Ozurdex, Allergan, Inc., Irvine, CA, USA) 15 days back for recalcitrant diabetic macular edema in the left eye came to us for a second opinion. On examination, his corrected distance visual acuity was 20/20 in the right eye and 20/40 in the left eye. Early cataractous changes were present in both eyes. The intraocular pressure was within normal limits. The Ozurdex implant was seen lodged in the posterior cortex of the crystalline lens in the left eye, confirmed on anterior segment optical coherence tomography (OCT) and ultrasound biomicroscopy. Fundus examination showed moderate nonproliferative diabetic retinopathy in both eyes with macular edema and epiretinal membrane in the left eye, confirmed on OCT. The patient was noncompliant and returned after 10 months. Interestingly, the implant was still present in the same location with the same vision and anterior segment findings as before. The OCT showed a reduction in macular edema. The patient was advised regular follow-up and cataract surgery at a later date.

show abstract

“…Management of complication from cases, arising out of intralenticular placement of Ozurdex with or without cataract formation has been described 1–3. Spontaneous migration, of an Ozurdex implant into the anterior chamber in the presence of anterior chamber implant has been described.…”

Section: Discussionmentioning

confidence: 99%

Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant

Sherman

Raman

2018

BMJ Case Rep

View full text Add to dashboard Cite

Ozurdex (Allergan, Irvine, California, USA) is a biodegradable sustained release intravitreal implant containing 0.7 mg dexamethasone in a solid polymer drug delivery system. In the UK, it is approved for use in patients with macular oedema secondary to retinal vein occlusion, diabetic maculopathy and non-infectious uveitis. Although the implant is meant to be injected into the vitreous cavity, it can be inadvertently injected into the crystalline lens. This can also migrate into the anterior chamber, under altered anatomical conditions of the anterior segment. We report a case of incompletely penetrated dexamethasone implant, in a patient undergoing treatment for macular oedema secondary to retinal vein occlusion. The partially penetrated implant was managed conservatively with a good outcome.

show abstract

Inadvertent Dexamethasone Implant Injection into the Lens Body Management

Abstract: The injection of an intravitreal dexamethasone implant (Ozurdex) into the lens body is an extremely rare complication that can be effectively and successfully managed with the surgical extraction of the implant from the lens body and implant of a 3-piece intraocular lens in the sulcus.

Cited by 33 publications

References 7 publications

Untitled

Untitled

Immortal Ozurdex: A 10-month follow-up of an intralenticular implant

Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant

Contact Info

Product

Resources

About